And also have to remember in practice, docs will have a much easier time prescribing for primary prevention off label if secondary prevention is given...
Agreed. Primary is going to be a coin flip decision for the FDA - panel leaning secondary, but point was made by several to let clinicians decide and give them access to the primary label. Overall, very positive panel.
Funny enough Konstam comes out in support of primary + secondary prevention. He appears to just be skeptical and like to challenge all sides. At the end he follows the logic and his logic tells him primary + secondary.
Funny enough Konstam comes out in support of primary + secondary prevention. He appears to just be skeptical and like to challenge all sides. At the end he follows the logic and his logic tells him primary + secondary. Definitely not fixed. The primary appears a coin flip still.
Market Data 
Markets 
AI
